Skip to main content
. 2021 Jan 14;10:586414. doi: 10.3389/fonc.2020.586414

Figure 4.

Figure 4

Disease-specific survival (DSS) of SLC41A3 in different cancer types. (A) DSS difference between groups in adrenocortical carcinoma (ACC). (B) DSS difference between groups in kidney renal clear cell carcinoma (KIRC). (C) DSS difference between groups in mesothelioma (MESO). (D) DSS difference between groups in uveal melanoma (UVM). (E) DSS difference between groups in cholangiocarcinoma (CHOL). (F) DSS difference between groups in kidney renal papillary cell carcinoma (KIRP). (G) DSS difference between groups in ovarian serous cystadenocarcinoma (OV). (H) DSS difference between groups in lung adenocarcinoma (LUAD). (I) DSS difference between groups in lymphoid neoplasm diffuse large B-cell lymphoma (DLBC). (J) DSS difference between groups in liver hepatocellular carcinoma (LIHC). (K) DSS difference between groups in pheochromocytoma and paraganglioma (PCPG). (L) DSS difference between groups in thymoma (THYM). (M) DSS difference between groups in head and neck squamous cell carcinoma (HNSC).